MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced it has entered into a securities purchase agreement with Janus Henderson Investors for a registered direct offering valued at approximately $20 million.
Under the agreement, Janus Henderson will acquire 20 million shares of common stock and warrants for an equal number of shares at $1.00 per share, matching the closing price on August 7, 2025. The warrants, exercisable immediately at $1.50 per share, will expire two years after issuance and may be called by the company if its stock trades above $2.50 for at least five days within a 30-day period.
If fully exercised, the warrants could generate up to an additional $30 million in gross proceeds. The offering, with Noble Capital Markets, Inc. acting as sole placement agent, is expected to close on or about August 11, 2025, subject to customary conditions.
Ocugen develops gene therapies for blindness diseases, targeting complex genetic disorders through its proprietary modifier gene therapy platform.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.